Maze Therapeutics Appoints City Hill Founder, Jonathan Lim, M.D., to its Board of DirectorsDownload PDF
South San Francisco, October 23, 2019 – Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Jonathan Lim, M.D., founder and managing partner at City Hill Ventures, has joined the company’s board of directors. In conjunction with his appointment, City Hill has made an undisclosed investment in Maze.
“Jonathan has a remarkable track record of building and scaling biotechnology companies that have made a difference for patients while also creating significant value for shareholders,” said Jason Coloma, Ph.D., chief executive officer of Maze. “Achieving Maze’s mission of leveraging genetic modifiers to develop targeted medicines will require the integration of a broad range of diverse perspectives. I believe that Jonathan’s experience in founding, funding, and leading biotechnology startups complements our existing directors well and will further support Maze’s ongoing growth and development.”
Jonathan’s experience in founding, funding, and leading biotechnology startups complements our existing directors well and will further support Maze’s ongoing growth and development
In addition to his role at City Hill, Dr. Lim is a venture partner at ARCH Venture Partners, chairman, chief executive officer and co-founder at Erasca, and chairman and co-founder at Boundless Bio. Prior to this, Dr. Lim’s most recent operational role was with precision oncology company Ignyta (RXDX), which he co-founded in 2011 and served as chairman, president and chief executive officer until its acquisition by Roche in 2018. He also previously served as chairman and co-founder of Bonti from 2015 until its 2018 acquisition by Allergan; chairman, chief executive officer and co-founder of Eclipse Therapeutics from 2011 to its 2012 acquisition by Bionomics (ASX:BNO); and president, chief executive officer and a board member of Halozyme Therapeutics (HALO) from 2003 to 2010. From 2004 to 2005 he also served as chairman of the board of Halozyme. Earlier in his career, Dr. Lim was a management consultant at McKinsey & Company, an NIH postdoctoral fellow at Harvard Medical School and Dana Farber Cancer Institute, and a general surgery resident at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. He holds B.S. and M.S. degrees from Stanford University, an M.D. from McGill University and an M.P.H. from Harvard University.
The company has made impressive progress in advancing its science, and I am pleased to be able to further support their efforts with this appointment and investment
“I believe Maze’s unique platform and approach to understanding and utilizing human genetics to identify targets and develop new medicines will be transformative in the future for patients with genetically defined diseases. In a short period, the company has made impressive progress in advancing its science, and I am pleased to be able to further support their efforts with this appointment and investment. I look forward to working with the team and helping them advance their mission for the future benefit of patients everywhere,” said Dr. Lim.
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for a number of genetically defined diseases. Maze is focused on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics and an array of drug discovery approaches. The Maze platform reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be best targeted with drug therapies. Maze was launched in 2019 by Third Rock Ventures, with funding from ARCH Venture Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments, City Hill and other undisclosed investors. Maze is based in South San Francisco. For more information please visit http://mazetx.com.
Katie Engleman, 1AB